No abstract available.
Hematoma, Epidural, Spinal* ; Humans ; Polycythemia Vera* ; Spinal Puncture* ; Subarachnoid Hemorrhage*

No abstract available.
Evoked Potentials ; Evoked Potentials, Somatosensory* ; Magnetic Resonance Imaging

No abstract available.
Facial Paralysis ; Myasthenia Gravis*

We report a case with squamous cell lung cancer with concomitant Guillain-Barre syndrome (GBS) as a paraneoplastic syndrome. A 67-year-old patient who was previously diagnosed as metastatic squamous cell lung cancer developed mild symmetrical weakness, paresthesia and sensory ataxia. Nerve conduction study showed sensorimotor polyneuropathy. Analysis of cerebrospinal fluid showed high tilter for monospecific anti-GD1b IgG antibody without onconeuronal antibodies. After treatment with intravenous immunoglobulin, the patient's symptoms improved.
Aged ; Antibodies ; Ataxia ; Cerebrospinal Fluid ; Guillain-Barre Syndrome* ; Humans ; Immunoglobulin G* ; Immunoglobulins ; Lung Neoplasms* ; Neural Conduction ; Paraneoplastic Syndromes ; Paresthesia ; Polyneuropathies

We reported a 48-year-old man with Behcet disease, who presented with right hemiparesis. His first brain MRI showed multiple enhanced lesions. During the recovery, he had an episode of left 6th nerve palsy without new lesions in a follow-up MRI. Third episode was cervical myelitis, resulting in respiratory difficulty and quadriplegia without any reflexes. The myelitis was not responsive to immunotherapy. He died of respiratory failure complicated with pneumonia. This is a rare case of full-blown neuro-Behcet disease.
Abducens Nerve Diseases ; Behcet Syndrome ; Brain ; Brain Stem ; Follow-Up Studies ; Humans ; Immunotherapy ; Magnetic Resonance Imaging ; Middle Aged ; Myelitis ; Paresis ; Pneumonia ; Quadriplegia ; Reflex ; Respiratory Insufficiency ; Spinal Cord

Amyloidosis is a systemic disorder associated with clonal plasma cell dyscrasia. Nephrotic syndrome, congestive heart failure, autonomic and peripheral neuropathy is often associated features in amyloidosis. Early diagnosis is most important because of different prognosis by stage. The diagnosis can be delayed since symptoms of amyloidosis may vary or nonspecific. We describe a patient of myeloma-associated amyloidosis, who showed orthostatic intolerance as the first symptom of the disease.
Amyloidosis* ; Diagnosis ; Early Diagnosis ; Heart Failure ; Humans ; Nephrotic Syndrome ; Orthostatic Intolerance* ; Paraproteinemias ; Peripheral Nervous System Diseases ; Prognosis

BACKGROUND: Sleep-related disturbances and sleep disorders are common in Parkinson's disease (PD) and have a great impact on daily life of PD patients. This study was done to find the sleep characteristics and sleep disturbing factors in PD patients according to disease severity through clinical interview and polysomnographic (PSG) study. METHODS: Fifty patients with PD (22 males, age 60.6 +/- 6.4, Hoehn and Yahr (HY) stage 2.7 +/- 1.0) were recruited and thoroughly interviewed about their sleep. PSG was performed on the patients taking routine antiparkinsonian medications. Patients were grouped into mild and moderate/severe group according to HY stage, and the results were compared between each group. RESULTS: Ninety-four percent of total patients had one or more sleep-related disturbances based on the interview or PSG. On interview, the moderate/severe group complained more insomnia and REM sleep behavior disorder (RBD) than mild group. In PSG findings, the moderate/severe group showed lower sleep efficiency, longer sleep latency, REM sleep latency, waking time after sleep onset, and higher prevalence of RBD. CONCLUSIONS: In this study, most patients with PD had sleep disturbances. Clinical interview and PSG findings revealed deterioration of sleep quality along the disease severity. Our results suggest that sleep disturbances in PD patients are prevalent and warrant clinical attention, especially to the patients with advanced disease.
Humans ; Male ; Parkinson Disease* ; Polysomnography ; Prevalence ; REM Sleep Behavior Disorder ; Sleep Wake Disorders ; Sleep Initiation and Maintenance Disorders ; Sleep, REM

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is characterized by progressive death of motor neurons in the cortex, brainstem, and spinal cord. Until now, many treatment strategies have been tested in ALS, but so far only Riluzole has shown efficacy of slightly slowing disease progression. The pathophysiological mechanisms underlying ALS are multifactorial, with a complex interaction between genetic factors and molecular pathways. Other motor neuron disease such as spinal muscular atrophy (SMA) and spinobulbar muscular atrophy (SBMA) are also progressive neurodegenerative disease with loss of motor neuron as ALS. This common thread of motor neuron loss has provided a target for the development of therapies for these motor neuron diseases. A better understanding of these pathogenic mechanisms and the potential pathological relationship between the various cellular processes have suggested novel therapeutic approaches, including stem cell and genetics-based strategies, providing hope for feasible treatment of ALS.
Amyotrophic Lateral Sclerosis* ; Brain Stem ; Disease Progression ; Hope ; Motor Neuron Disease ; Motor Neurons ; Muscular Atrophy, Spinal ; Muscular Disorders, Atrophic ; Neurodegenerative Diseases ; Riluzole ; Spinal Cord ; Stem Cells

No abstract available.
Acyclovir ; Humans

No abstract available.
Brain Stem ; Coma ; Encephalitis ; Humans ; Immunotherapy